相关实验视频

Updated: Apr 7, 2026

Ligand Nano-cluster Arrays in a Supported Lipid Bilayer

Ligand Nano-cluster Arrays in a Supported Lipid Bilayer

Published on: April 23, 2017

在脂质体原细胞组合中集成的腺素触发动态和短暂的aptamer网络

Yu Ouyang¹, Yang Sung Sohn², Xinghua Chen¹

¹Institute of Chemistry, The Hebrew University of Jerusalem, Jerusalem 91904, Israel.

Journal of the American Chemical Society

|May 22, 2025

概括

研究人员开发了一种基于DNA的新系统,使用腺 (AD) 和腺除氨酶 (ADA) 来创建动态电路. 这种系统被整合到原细胞中, 成功向并诱导乳腺癌细胞的亡, 显示出基因治疗的前景.

科学领域:

生物化学和分子生物学
合成生物学
纳米技术

背景情况:

基于核酸的短暂消散反应电路和结构动态网络是模拟生物系统的新兴领域.
之前的研究利用酶,DNA酶或光来控制DNA网络,将其整合到原细胞中是一个关键挑战.
开发动态DNA电路的多功能框架及其在原细胞模型中的应用是一个活跃的研究领域.

研究的目的:

引入一种多功能氨酸 (AD) /氨酸脱氨酶 (ADA) 识别/催化框架,用于驱动短暂的DNA酶电路和消散性结构动态网络.
将这些AD/ADA驱动的短暂框架整合到脂质体组合中作为原细胞模型.
展示这些基因细胞在向癌症基因治疗中的潜力.

主要方法:

使用AD/ADA系统开发了一种全性AD稳定DNA酶电路和一个消散性AD稳定结构动态网络.
将AD/ADA驱动的短暂框架集成到脂质体组件中以创建原细胞模型.
用ATP稳定DNA酶对EGR-1mRNA进行功能化,并将其与MCF-7乳腺癌细胞融合.

主要成果:

成功创建了由AD/ADA框架驱动的短暂的,全质控制的DNA酶电路和消散的结构动态网络.
在基于脂质体的原细胞模型中展示了这些动态DNA系统的整合.
在MCF-7乳腺癌细胞中通过提供EGR-1mRNA分裂DNA酶的功能化脂质体实现了选择性亡.

结论:

该AD/ADA识别/催化框架为构建短暂的,全osterically控制的基于DNA的电路和网络提供了一个多功能平台.
将这些动态DNA系统整合到原细胞模型中为开发先进的生物系统提供了有前途的方法.
这项研究展示了基因基因治疗的工程原细胞的潜力,特别是通过mRNA降解诱导乳腺癌细胞的亡.

更多相关视频

On-Chip Octanol-Assisted Liposome Assembly for Bioengineering

On-Chip Octanol-Assisted Liposome Assembly for Bioengineering

Published on: March 17, 2023

Author Spotlight: Tackling Challenges in Synthetic Cell Engineering

Author Spotlight: Tackling Challenges in Synthetic Cell Engineering

Published on: April 12, 2024

相关概念视频

Receptor-mediated Endocytosis

Receptor-mediated Endocytosis

Drug Absorption Mechanism: Carrier-Mediated Membrane Transport

Drug Absorption Mechanism: Carrier-Mediated Membrane Transport

Certain large, lipid-insoluble drug molecules that resemble amino acids, peptides, or glucose, require specialized carrier proteins to facilitate their diffusion across cell membranes. This transport can occur through either facilitated diffusion, which does not require energy input, or active transport, which does require energy input.
Facilitated diffusion is a passive process that utilizes human Solute Carrier (SLC) transporters. These transporters bind to the drug, undergo structural...

Carrier-Mediated Transport

Carrier-Mediated Transport

Carrier-mediated transport is a pivotal process in drug absorption, particularly for lipid-insoluble drugs, and encompasses facilitated diffusion and active transport. Facilitated diffusion allows drugs to move along their concentration gradient without energy expenditure, while active transport utilizes ATP to drive drug movement against this gradient.
Active transport involves two types of membrane-spanning transporters: uptake and efflux. Uptake transporters are expressed in the small...

Modified-Release Drug Delivery Systems: Site-Targeted

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.